Toygar Okan, Guess Matthew G, Youssef David S, Miller Daniel M
*Cincinnati Eye Institute, Cincinnati, Ohio; †Department of Ophthalmology, Faculty of Medicine, Bahcesehir University; and ‡Department of Ophthalmology, University of Cincinnati School of Medicine, Cincinnati, Ohio.
Retina. 2016 Nov;36(11):2150-2157. doi: 10.1097/IAE.0000000000001035.
To assess the long-term visual acuity results for intravitreal bevacizumab therapy in the treatment of subretinal neovascular membrane (SRNVM) secondary to idiopathic macular telangiectasia (Mactel) Type 2.
This retrospective review of a consecutive, interventional case series includes patients with SRNVM secondary to Mactel Type 2 who were seen at Cincinnati Eye Institute from February 2006 to December 2014. Best-corrected visual acuity, fluorescein angiography, and optical coherence tomography measurements were performed. Exclusion criteria were the following: Mactel Type 2 patients without SRNVM, Mactel Type 1 patients, patients who had SRNVM or macular edema related to other maculopathies, and patients who had pars plana vitrectomy or laser treatment to the macula during the course of care or before their first visit.
Twenty-five eyes of 20 patients with SRNVM secondary to Mactel Type 2 were included in the study. The mean baseline best-corrected visual acuity was 20/91 (median: 20/69) and the mean final best-corrected visual acuity was 20/62 (median: 20/60) at the last visit (P < 0.0001). The mean number of injections was 8.4 ± 11.1 (range: 2-53, median: 4). The mean pretreatment central macular thickness of 254 μm improved to 205 μm at the final visit (P = 0.011). No complications related to intravitreal bevacizumab injection were noted during the mean follow-up time of 40.8 ± 33.7 months (range: 4-108 months, median: 24 months).
Intravitreal bevacizumab therapy is an effective long-term treatment modality for SRNVM secondary to Mactel Type 2 based on improvement in best-corrected visual acuity and associated reduction in central macular thickness.
评估玻璃体内注射贝伐单抗治疗继发于2型特发性黄斑毛细血管扩张症（Mactel）的视网膜下新生血管膜（SRNVM）的长期视力结果。
本回顾性研究连续纳入了一系列干预性病例，研究对象为2006年2月至2014年12月在辛辛那提眼科学院就诊的继发于2型Mactel的SRNVM患者。进行了最佳矫正视力、荧光素血管造影和光学相干断层扫描测量。排除标准如下：无SRNVM的2型Mactel患者、1型Mactel患者、患有与其他黄斑病变相关的SRNVM或黄斑水肿的患者，以及在治疗过程中或首次就诊前接受过玻璃体切除术或黄斑激光治疗的患者。
本研究纳入了20例继发于2型Mactel的SRNVM患者的25只眼。最后一次就诊时，平均基线最佳矫正视力为20/91（中位数：20/69），平均最终最佳矫正视力为20/62（中位数：20/60）（P<0.0001）。平均注射次数为8.4±11.1次（范围：2 - 53次，中位数：4次）。平均术前中心黄斑厚度为254μm，最后一次就诊时改善至205μm（P = 0.011）。在平均40.8±33.7个月（范围：4 - 108个月，中位数：24个月）的随访时间内，未观察到与玻璃体内注射贝伐单抗相关的并发症。
基于最佳矫正视力的改善以及中心黄斑厚度的相应降低，玻璃体内注射贝伐单抗治疗是继发于2型Mactel的SRNVM的一种有效的长期治疗方式。
